Sernova Corp. | Income Statement

Fiscal year is November-October. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
713.30
779.00
497.10
7.60
39.90
64.50
Gross Income
713.30
779.00
497.10
7.60
39.90
64.50
SG&A Expense
1,649.50
2,163.60
2,553.30
2,494.00
2,603.60
3,641.90
EBIT
2,362.80
2,942.60
3,050.30
2,501.60
2,643.40
3,706.40
Non Operating Income/Expense
1.60
3.70
5.80
18.50
36.40
10.20
Interest Expense
-
-
-
9.70
13.80
9.70
Pretax Income
2,300.50
2,895.10
3,024.10
2,499.60
2,639.50
3,698.60
Income Tax
297.60
149.00
164.60
-
-
-
Consolidated Net Income
2,002.90
2,746.10
2,859.50
2,499.60
2,639.50
3,698.60
Net Income
2,002.90
2,746.10
2,859.50
2,499.60
2,639.50
3,698.60
Net Income After Extraordinaries
2,002.90
2,746.10
2,859.50
2,499.60
2,639.50
3,698.60
Net Income Available to Common
2,002.90
2,746.10
2,859.50
2,499.60
2,639.50
3,698.60
EPS (Basic)
0.02
0.02
0.02
0.02
0.02
0.02
Basic Shares Outstanding
123,120.50
130,050.10
136,119.80
147,959.60
158,242.80
159,461.10
EPS (Diluted)
0.02
0.02
0.02
0.02
0.02
0.02
Diluted Shares Outstanding
123,120.50
130,050.10
136,119.80
147,959.60
158,242.80
159,461.10
EBITDA
1,649.50
2,163.60
2,553.30
2,494.00
2,603.60
3,641.90
Non-Operating Interest Income
63.80
51.10
32.00
30.10
54.20
27.70

About Sernova

View Profile
Address
700 Collip Circle
London Ontario N6G 4X8
Canada
Employees -
Website http://www.sernova.com
Updated 07/08/2019
Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. It also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes.